WEE1 and systemic lupus erythematosus: The therapeutic armamentarium has expanded with the approval of the first two biologic agents for SLE, belimumab and anifrolumab, alongside emerging molecular therapies such as protein kinase inhibitors (including JAK inhibitors), and new approaches to lupus nephritis induction using multitarget regimens that combine standard therapy with belimumab or calcineurin inhibitors.